MADRIGAL PHARMACEUTICALS, INC. (MDGL) FY2025 10-K Annual Report
MADRIGAL PHARMACEUTICALS, INC. (MDGL) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 19, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
MADRIGAL PHARMACEUTICALS, INC. FY2025 10-K Analysis
Business Overview
- • Core business model: development and commercialization of pharmaceutical therapies for liver diseases, primarily noncirrhotic MASH
- • New product: Launch and full-year commercialization of Rezdiffra in U.S. (approved Mar 2024) and market entry in Germany (Sep 2025)
- • Strategic shift: Expansion of commercial infrastructure and geographic presence in Europe with emphasis on Rezdiffra sales growth
- • Quantitative highlight: Product revenue surged to $958.4M in 2025 from $180.1M in 2024, with SG&A expenses increasing 87% to $813.8M reflecting expanded commercial activities
- • Noteworthy fact: Entered $500M senior secured credit facility in July 2025, repaid and terminated prior $250M Hercules Loan Facility, signaling strengthened financial positioning
Management Discussion & Analysis
- • No revenue or YoY change figures provided in the MD&A
- • No profitability or margin percentages disclosed
- • No segment performance data included
- • No cash flow, buybacks, dividends, or capex numbers reported
- • Forward-looking focus on expanding Rezdiffra use via MAESTRO-NASH OUTCOMES trial and pipeline development of MGL-2086, ervogastat, siRNA programs
Risk Factors
- • Regulatory risk: accelerated approval of Rezdiffra under FDA Subpart H pathway contingent on completing MAESTRO-NASH trials for full approval
- • Geopolitical/macro risk: U.S. Medicare drug price negotiation program starting 2026 may cap prices and impose rebates on high-spend drugs like Rezdiffra
- • Operational risk: dependence on third-party manufacturers to meet cGMP standards and commercial supply demands for Rezdiffra
- • Competitive risk: potential competition from off-label use of marketed products and future MASH therapies impacting Rezdiffra market share
- • Financial risk: reliance on successful third-party payor coverage and reimbursement, including Medicare, Medicaid, and PBMs, to support Rezdiffra sales
MADRIGAL PHARMACEUTICALS, INC. FY2025 Key Financial MetricsXBRL
Revenue
$958M
▲ +432.1% YoY
Net Income
-$288M
▲ +38.1% YoY
Operating Margin
-31.3%
▲ +24508bp YoY
Net Margin
-30.1%
▲ +22856bp YoY
ROE
-47.8%
▲ +1393bp YoY
Total Assets
$1.3B
▲ +20.9% YoY
EPS (Diluted)
$-12.85
▲ +41.3% YoY
Operating Cash Flow
-$190M
▲ +58.4% YoY
Source: XBRL data from MADRIGAL PHARMACEUTICALS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on MADRIGAL PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.